Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-BioB Cohort Study: the neutralizing antibody response to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for virus control and survival

View ORCID ProfileStefania Dispinseri, View ORCID ProfileMassimiliano Secchi, View ORCID ProfileMaria Franca Pirillo, View ORCID ProfileMonica Tolazzi, View ORCID ProfileMartina Borghi, View ORCID ProfileCristina Brigatti, View ORCID ProfileMaria Laura De Angelis, View ORCID ProfileMarco Baratella, View ORCID ProfileElena Bazzigaluppi, View ORCID ProfileGiulietta Venturi, Francesca Sironi, View ORCID ProfileAndrea Canitano, View ORCID ProfileIlaria Marzinotto, View ORCID ProfileCristina Tresoldi, View ORCID ProfileFabio Ciceri, View ORCID ProfileLorenzo Piemonti, View ORCID ProfileDonatella Negri, View ORCID ProfileAndrea Cara, View ORCID ProfileVito Lampasona, View ORCID ProfileGabriella Scarlatti
doi: https://doi.org/10.1101/2021.02.17.21251929
Stefania Dispinseri
1Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stefania Dispinseri
Massimiliano Secchi
2Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Massimiliano Secchi
Maria Franca Pirillo
3National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maria Franca Pirillo
Monica Tolazzi
1Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Monica Tolazzi
Martina Borghi
4Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martina Borghi
Cristina Brigatti
2Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cristina Brigatti
Maria Laura De Angelis
5Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maria Laura De Angelis
Marco Baratella
1Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marco Baratella
Elena Bazzigaluppi
2Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elena Bazzigaluppi
Giulietta Venturi
4Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giulietta Venturi
Francesca Sironi
1Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Canitano
3National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrea Canitano
Ilaria Marzinotto
2Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ilaria Marzinotto
Cristina Tresoldi
6Molecular Hematology Unit, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cristina Tresoldi
Fabio Ciceri
7Hematology and Bone Marrow Transplantation Unit, IRCCS Ospedale San Raffaele, Milan, Italy
8School of Medicine and Surgery, Università Vita-Salute San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fabio Ciceri
Lorenzo Piemonti
2Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
8School of Medicine and Surgery, Università Vita-Salute San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lorenzo Piemonti
Donatella Negri
4Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Donatella Negri
Andrea Cara
3National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrea Cara
Vito Lampasona
2Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vito Lampasona
Gabriella Scarlatti
1Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gabriella Scarlatti
  • For correspondence: scarlatti.gabriella@hsr.it
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Understanding how antibody to SARS-CoV-2 evolve during infection may provide important insight into therapeutic approaches to prevent fatal COVID-19 illness and vaccines. Here, we profile the antibody response of 162 well-characterized COVID-19 symptomatic patients followed longitudinally for up to eight months from symptom onset. Using two newly developed assays we detect SARS-CoV-2 neutralization and antibodies binding to Spike antigens and nucleoprotein as well as to Spike S2 antigen of seasonal beta-coronaviruses, and to hemagglutinin of the H1N1 flu virus. Presence of neutralizing antibodies withing the first weeks from symptom onset correlates with time to a negative swab result (p=0.002) while lack of neutralization with an increased risk of a fatal disease outcome (HR 2.918, 95%CI 1.321-6.449; p=0.008). Neutralizing antibody titers progressively drop after 5-8 weeks but are still detectable up to 8 months in the majority of recovered patients regardless of age or co-morbidities. IgG to Spike antigens are the best correlate of neutralization. Antibody responses to seasonal coronaviruses are temporary boosted and parallel those to SARS-CoV-2 without dampening the specific response or worsening disease progression. Thus, a compromised immune response to the Spike rather than an enhanced one is a major trait of patients with critical conditions. Patients should be promptly identified and immediately start therapeutic interventions aimed at restoring their immunity.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04318366

Funding Statement

The work performed at IRCCS Ospedale San Raffaele (OSR) was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (COVID-2020-12371617). The work by Viral Evolution and Transmission Unit, OSR, and Istituto Superiore di Sanita (ISS) was funded by EAVI2020, the European Union Horizon 2020 research and innovation programme under grant agreement No. 681137. ISS received support in part by NATO multi-year Project No. G5817: New and Validated Tools for the Diagnosis and follow-up of SARS-CoV-2 Infected Individuals, and by ISS internal funds. The Fondation Dormeur, Vaduz donated to Viral Evolution and Transmission Unit for laboratory instruments relevant to this project.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

the Review Board (RB) of IRCCS San Raffaele Hospital reviewed and approved the COVID-biob protocol, COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor; an observational cohort with non-probability sampling method (RB protocol number 34/int/2020) and in specific for the immunological studies (RB protocol number 68/INT/2020).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 19, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-BioB Cohort Study: the neutralizing antibody response to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for virus control and survival
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-BioB Cohort Study: the neutralizing antibody response to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for virus control and survival
Stefania Dispinseri, Massimiliano Secchi, Maria Franca Pirillo, Monica Tolazzi, Martina Borghi, Cristina Brigatti, Maria Laura De Angelis, Marco Baratella, Elena Bazzigaluppi, Giulietta Venturi, Francesca Sironi, Andrea Canitano, Ilaria Marzinotto, Cristina Tresoldi, Fabio Ciceri, Lorenzo Piemonti, Donatella Negri, Andrea Cara, Vito Lampasona, Gabriella Scarlatti
medRxiv 2021.02.17.21251929; doi: https://doi.org/10.1101/2021.02.17.21251929
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
COVID-BioB Cohort Study: the neutralizing antibody response to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for virus control and survival
Stefania Dispinseri, Massimiliano Secchi, Maria Franca Pirillo, Monica Tolazzi, Martina Borghi, Cristina Brigatti, Maria Laura De Angelis, Marco Baratella, Elena Bazzigaluppi, Giulietta Venturi, Francesca Sironi, Andrea Canitano, Ilaria Marzinotto, Cristina Tresoldi, Fabio Ciceri, Lorenzo Piemonti, Donatella Negri, Andrea Cara, Vito Lampasona, Gabriella Scarlatti
medRxiv 2021.02.17.21251929; doi: https://doi.org/10.1101/2021.02.17.21251929

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (202)
  • Anesthesia (55)
  • Cardiovascular Medicine (495)
  • Dentistry and Oral Medicine (91)
  • Dermatology (57)
  • Emergency Medicine (170)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (217)
  • Epidemiology (5744)
  • Forensic Medicine (3)
  • Gastroenterology (220)
  • Genetic and Genomic Medicine (881)
  • Geriatric Medicine (89)
  • Health Economics (233)
  • Health Informatics (776)
  • Health Policy (399)
  • Health Systems and Quality Improvement (256)
  • Hematology (105)
  • HIV/AIDS (186)
  • Infectious Diseases (except HIV/AIDS) (6576)
  • Intensive Care and Critical Care Medicine (396)
  • Medical Education (119)
  • Medical Ethics (28)
  • Nephrology (94)
  • Neurology (856)
  • Nursing (45)
  • Nutrition (143)
  • Obstetrics and Gynecology (166)
  • Occupational and Environmental Health (265)
  • Oncology (520)
  • Ophthalmology (168)
  • Orthopedics (44)
  • Otolaryngology (107)
  • Pain Medicine (48)
  • Palliative Medicine (22)
  • Pathology (150)
  • Pediatrics (256)
  • Pharmacology and Therapeutics (147)
  • Primary Care Research (116)
  • Psychiatry and Clinical Psychology (989)
  • Public and Global Health (2263)
  • Radiology and Imaging (380)
  • Rehabilitation Medicine and Physical Therapy (175)
  • Respiratory Medicine (313)
  • Rheumatology (109)
  • Sexual and Reproductive Health (83)
  • Sports Medicine (83)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)